Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerance of cryopreserved autologous stromal vascular fraction for refractory ano-perineal fistulas in Crohn's disease
2024-519740-32-00Phase 2Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Jun 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived stromal vascular fraction cells in Crohn's disease, sponsored by Assistance Publique–Hôpitaux de Marseille. Primary endpoints: Absence of local infectious complications, Absence of general infectious complications and 2 more. Planned start Jun 2025; status: authorised.
02
Drugs
autologous adipose-derived stromal vascular fraction cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-519740-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519740-32-00.